DCT

1:21-cv-01710

Galderma Laboratories LP v. Lupin Inc

Log In

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:21-cv-01710, D. Del., 12/03/2021
  • Venue Allegations: Venue is alleged to be proper in the District of Delaware because Defendant Lupin Inc. is a Delaware corporation and has previously consented to jurisdiction in the district.
  • Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA seeking approval to market a generic 40 mg doxycycline capsule constitutes an act of infringement of six patents related to once-daily, low-dose tetracycline formulations.
  • Technical Context: The technology concerns controlled-release oral pharmaceutical formulations designed to deliver the anti-inflammatory benefits of doxycycline at sub-antimicrobial doses for treating chronic conditions like rosacea, thereby avoiding side effects associated with long-term antibiotic use.
  • Key Procedural History: The complaint notes that in a previous litigation, claims of the lead '532 patent were found to be not invalid and infringed by a different Lupin ANDA product, a judgment that was affirmed by the U.S. Court of Appeals for the Federal Circuit. This history may influence assessments of willfulness and the viability of certain invalidity defenses. Several of the asserted patents have also survived Inter Partes Review (IPR) proceedings at the USPTO.

Case Timeline

Date Event
2003-04-07 Priority Date for all Patents-in-Suit
2010-07-06 U.S. Patent No. 7,749,532 Issues
2012-06-26 U.S. Patent No. 8,206,740 Issues
2013-03-12 U.S. Patent No. 8,394,405 Issues
2013-03-12 U.S. Patent No. 8,394,406 Issues
2013-06-25 U.S. Patent No. 8,470,364 Issues
2014-04-29 U.S. Patent No. 8,709,478 Issues
2015-05-13 Inter Partes Review Certificate Issued for '740 Patent
2021-10-21 Defendant Lupin Inc. sends Paragraph IV Notice Letter to Plaintiffs
2021-12-03 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 7,749,532 - "Once Daily Formulations of Tetracyclines"

  • Issued: July 6, 2010

The Invention Explained

  • Problem Addressed: The patent describes that while doxycycline is effective for its anti-inflammatory properties in treating conditions like rosacea and periodontal disease, its long-term use as an antibiotic can lead to undesirable side effects, such as the disruption of healthy intestinal flora and the development of antibiotic-resistant organisms. Furthermore, traditional twice-daily dosing regimens raise concerns about patient compliance. (’532 Patent, col. 2:1-17).
  • The Patented Solution: The invention is a once-daily oral formulation of doxycycline at a sub-antimicrobial dose (less than 50 mg) designed to achieve and maintain steady-state blood levels high enough for a therapeutic anti-inflammatory effect but low enough to avoid significant antibacterial activity. This is achieved through a composition containing both an immediate-release (IR) component and a delayed-release (DR) component, which together provide a specific pharmacokinetic profile over a 24-hour period. (’532 Patent, col. 2:21-41, 46-59).
  • Technical Importance: This formulation strategy enabled the chronic use of doxycycline as an anti-inflammatory agent, decoupling its therapeutic benefits from its antibiotic effects and improving patient convenience with once-daily dosing. (’532 Patent, col. 1:5-17).

Key Claims at a Glance

  • The complaint asserts at least independent claim 1. (Compl. ¶33).
  • Claim 1 of the ’532 Patent requires:
    • An oral pharmaceutical composition of doxycycline.
    • The composition, at a once-daily dosage, gives steady state blood levels of doxycycline between 0.1 µg/ml and 1.0 µg/ml.
    • The composition consists of an immediate release (IR) portion with about 30 mg of doxycycline.
    • The composition consists of a delayed release (DR) portion with about 10 mg of doxycycline.
    • The DR portion is in the form of pellets coated with at least one enteric polymer.
    • The composition consists of one or more pharmaceutically acceptable excipients.
  • The complaint does not explicitly reserve the right to assert dependent claims.

U.S. Patent No. 8,206,740 - "Once Daily Formulations of Tetracyclines"

  • Issued: June 26, 2012

The Invention Explained

  • Problem Addressed: As a continuation of the application leading to the ’532 Patent, the ’740 patent addresses the same technical problem of enabling the long-term, once-daily administration of sub-antimicrobial doxycycline for its anti-inflammatory effects while minimizing antibiotic side effects and improving patient compliance. (’740 Patent, col. 2:1-17).
  • The Patented Solution: The patent claims a pharmaceutical composition with a specific total dose of doxycycline (40 mg) divided into an IR portion (30 mg) and a DR portion (10 mg). This combination is designed to produce a specific, therapeutically effective, sub-antimicrobial blood concentration level when administered once per day. (’740 Patent, col. 2:28-41, col. 12:44-60).
  • Technical Importance: This patent further protects the core concept of a dual-release, low-dose, once-daily doxycycline formulation for chronic inflammatory conditions. (’740 Patent, col. 1:5-17).

Key Claims at a Glance

  • The complaint asserts at least independent claim 1. (Compl. ¶33).
  • Claim 1 of the ’740 Patent requires:
    • An oral pharmaceutical composition of doxycycline.
    • The composition, at a once-daily dosage, gives steady state blood levels of doxycycline between 0.1 µg/ml and 1.0 µg/ml.
    • The composition consists of an immediate release (IR) portion comprising 30 mg doxycycline.
    • The composition consists of a delayed release (DR) portion comprising 10 mg doxycycline.
    • Optionally, one or more pharmaceutically acceptable excipients.
  • The complaint does not explicitly reserve the right to assert dependent claims.

Multi-Patent Capsule: U.S. Patent No. 8,394,405

  • Patent Identification: U.S. Patent No. 8394405, "Once Daily Formulations of Tetracyclines," issued March 12, 2013.
  • Technology Synopsis: This patent, from the same family, claims a composition of about 40 mg total doxycycline formulated with a specific ratio of immediate-release (70-80%) to delayed-release (20-30%) components. The formulation is designed to achieve the same therapeutic sub-antimicrobial blood levels as the parent patents. (’405 Patent, col. 2:28-41, col. 12:1-11).
  • Asserted Claims: At least Claim 1. (Compl. ¶33).
  • Accused Features: Lupin's ANDA Product is alleged to be a 40 mg doxycycline capsule that meets the compositional limitations of the patent. (Compl. ¶¶7, 33).

Multi-Patent Capsule: U.S. Patent No. 8,394,406

  • Patent Identification: U.S. Patent No. 8394406, "Once Daily Formulations of Tetracyclines," issued March 12, 2013.
  • Technology Synopsis: This patent claims a method of treating rosacea by administering a once-daily oral pharmaceutical composition of about 40 mg total doxycycline. The composition consists of 70-80% of the doxycycline in an immediate-release formulation and 20-30% in a delayed-release formulation. (’406 Patent, col. 2:28-41, col. 13:17-33).
  • Asserted Claims: At least Claim 1. (Compl. ¶33).
  • Accused Features: Lupin's submission of its ANDA, which seeks approval to market the product for uses covered by the patent, is the alleged act of infringement. (Compl. ¶¶7, 34).

Multi-Patent Capsule: U.S. Patent No. 8,470,364

  • Patent Identification: U.S. Patent No. 8470364, "Once Daily Formulations of Tetracyclines," issued June 25, 2013.
  • Technology Synopsis: This patent claims an oral pharmaceutical composition consisting of an immediate-release formulation with about 30 mg doxycycline and a delayed-release formulation with about 10 mg doxycycline. The composition is designed to achieve specific steady-state blood levels when administered once daily. (’364 Patent, col. 2:28-41, col. 12:1-10).
  • Asserted Claims: At least Claim 1. (Compl. ¶33).
  • Accused Features: Lupin's ANDA Product is alleged to be a 40 mg doxycycline capsule that meets the claimed compositional limitations. (Compl. ¶¶7, 33).

Multi-Patent Capsule: U.S. Patent No. 8,709,478

  • Patent Identification: U.S. Patent No. 8709478, "Once Daily Formulations of Tetracyclines," issued April 29, 2014.
  • Technology Synopsis: This patent claims a method for treating rosacea by administering a once-daily composition that consists of an immediate-release portion of about 30 mg doxycycline and a delayed-release portion of about 10 mg doxycycline. This method is intended to achieve the desired sub-antimicrobial therapeutic effect. (’478 Patent, col. 2:28-41, col. 13:3-16).
  • Asserted Claims: At least Claim 1. (Compl. ¶33).
  • Accused Features: The alleged infringement is Lupin's filing of its ANDA seeking approval to market its product for uses, such as treating rosacea, that are covered by the patent. (Compl. ¶¶7, 34).

III. The Accused Instrumentality

Product Identification

The accused instrumentality is "Lupin's ANDA Product," identified as Doxycycline Capsules, 40 mg, for which Lupin Inc. submitted ANDA No. 216631 to the FDA. (Compl. ¶7).

Functionality and Market Context

The complaint alleges that Lupin's ANDA Product is a generic version of Plaintiffs’ commercial product, ORACEA® (doxycycline, USP) 40 mg Capsules. (Compl. ¶33). It is further alleged that Lupin has submitted bioequivalence data to the FDA comparing its product to ORACEA®. (Compl. ¶33). The product's intended function is therefore to deliver a 40 mg dose of doxycycline for therapeutic use. The infringement allegations are based on the premise that this generic product is formulated in a way that practices the specific release profiles claimed in the patents-in-suit. (Compl. ¶¶33-34).

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

The complaint contains high-level infringement allegations typical of an initial ANDA filing, stating on information and belief that the accused product meets the limitations of at least Claim 1 of each patent-in-suit. (Compl. ¶33). The following charts summarize these allegations based on the explicit claim language.

'532 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
An oral pharmaceutical composition of doxycycline, which at a once-daily dosage will give steady state blood levels of doxycycline of a minimum of 0.1 µg/ml and a maximum of 1.0 µg/ml... Lupin's ANDA Product is alleged to be a 40 mg doxycycline capsule that, upon information and belief based on its bioequivalence to ORACEA®, is formulated to achieve the claimed pharmacokinetic profile. ¶33 col. 11:65-12:1
...the composition consisting of (i) an immediate release (IR) portion comprising a drug, wherein the drug consists of about 30 mg doxycycline... Lupin's ANDA Product allegedly contains an immediate release component of about 30 mg doxycycline. ¶33 col. 12:1-3
...(ii) a delayed release (DR) portion comprising a drug, wherein the drug consists of about 10 mg doxycycline, in which the DR portion is in the form of pellets coated with at least one enteric polymer... Lupin's ANDA Product allegedly contains a delayed release component of about 10 mg doxycycline formulated as pellets with an enteric coating. ¶33 col. 12:3-6

'740 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
An oral pharmaceutical composition of doxycycline, which at a once-daily dosage will give steady state blood levels of doxycycline of a minimum of 0.1 µg/ml and a maximum of 1.0 µg/ml... Lupin's ANDA Product is alleged to be a 40 mg doxycycline capsule that, upon information and belief based on its bioequivalence to ORACEA®, is formulated to achieve the claimed pharmacokinetic profile. ¶33 col. 12:50-54
...the composition consisting of (i) an immediate release (IR) portion comprising 30 mg doxycycline... Lupin's ANDA Product allegedly contains an immediate release component of 30 mg doxycycline. ¶33 col. 12:55-56
...(ii) a delayed release (DR) portion comprising 10 mg doxycycline... Lupin's ANDA Product allegedly contains a delayed release component of 10 mg doxycycline. ¶33 col. 12:57-58

Identified Points of Contention

  • Technical Questions: Since the complaint lacks specific technical details about Lupin's product, the central dispute will involve evidence developed during discovery. Key questions include: What is the precise formulation of Lupin's ANDA product, including its excipients and release mechanisms? Does empirical data from Lupin's ANDA filing or subsequent testing confirm that its product achieves the steady-state blood levels required by the claims? Does the delayed-release component of Lupin's product meet the "pellets coated with at least one enteric polymer" limitation of the ’532 Patent, or does it use a different DR technology?
  • Scope Questions: The case will likely involve disputes over the meaning of claim terms. A primary question will be the proper construction of "about 30 mg" and "about 10 mg." The parties may dispute whether Lupin's specific dosages fall within the scope of "about" as understood in the context of the patent and the pharmaceutical arts.

V. Key Claim Terms for Construction

  • The Term: "about 30 mg doxycycline" and "about 10 mg doxycycline" (from Claim 1 of the ’532 and ’740 Patents, among others).

  • Context and Importance: The definition of "about" is critical for determining literal infringement. The case may turn on whether the actual dosages in Lupin's ANDA product, if not precisely 30 mg and 10 mg, are captured by this term. Practitioners may focus on this term because even small deviations in dosage in an ANDA formulation could be used to design around a patent claim if "about" is construed narrowly.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specification uses flexible ratio language, such as "ratios of about 70:30 to about 80:20, and most preferred 75:25, IR:DR," which corresponds to the 30 mg/10 mg split. This suggests the inventors contemplated a range, not just a single precise value. (’532 Patent, col. 2:55-57).
    • Evidence for a Narrower Interpretation: The claims recite specific numerical values (30 and 10), and the patent's detailed examples calculate fill weights to achieve these specific dosages. (’532 Patent, col. 10:10-20). A defendant could argue that "about" should be interpreted narrowly to encompass only minor variations consistent with standard pharmaceutical manufacturing tolerances.

  • The Term: "steady state blood levels of doxycycline of a minimum of about 0.1 µg/ml and a maximum of about 1.0 µg/ml" (from Claim 1 of the ’532 and ’740 Patents, among others).

  • Context and Importance: This functional language defines the invention by its pharmacokinetic result, not just its physical structure. Infringement requires proof that the accused product achieves this specific in vivo profile. The dispute will center on what evidence is required to prove this element and whether Lupin's product, based on its bioequivalence data, meets it.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The patent's primary goal is to achieve a "sub-antimicrobial" effect, with the specification describing the 0.1 to 1.0 µg/ml range as achieving this goal. (’532 Patent, col. 2:21-41). This purpose-driven language may support a construction that focuses on achieving the overall therapeutic window rather than rigidly adhering to the exact numerical boundaries.
    • Evidence for a Narrower Interpretation: The patent explicitly distinguishes the claimed blood levels from those achieved by prior art antibiotic dosages. The specification also provides a "more preferred" range of 0.3 µg/ml to 0.8 µg/ml, suggesting the claimed 0.1 to 1.0 µg/ml range was a deliberately chosen boundary. (’532 Patent, col. 3:55-57). Figures 4-6 illustrate specific pharmacokinetic curves, which could be used to argue for a less flexible interpretation of the required performance.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that Lupin Inc. and Lupin Limited "actively and knowingly caused to be submitted, assisted with, participated in, contributed to, or directed the submission of ANDA No. 216631." (Compl. ¶35). It further alleges that if Lupin's product is approved and launched, its actions would constitute induced and contributory infringement. (Compl. ¶36).
  • Willful Infringement: Willfulness is alleged based on Lupin's purported pre-suit knowledge of the patents-in-suit and its alleged lack of a reasonable basis to believe it did not infringe. (Compl. ¶39). This allegation is substantially strengthened by the complaint's reference to prior litigation where Lupin was found to have infringed the '532 patent. (Compl. ¶40).

VII. Analyst’s Conclusion: Key Questions for the Case

  • A central legal issue will be the impact of prior litigation: to what extent will the previous judgment of infringement and validity against Lupin concerning the ’532 patent preclude or influence defenses in this case, and how will it bear on the allegations of willful infringement regarding the entire patent family?
  • A key evidentiary question will be one of pharmacokinetic proof: what technical data will emerge during discovery to demonstrate whether Lupin’s 40 mg doxycycline capsule, alleged to be bioequivalent to the branded product, actually achieves the specific steady-state blood plasma concentrations defined as a critical limitation in the asserted claims?
  • The dispute is also likely to involve a question of definitional scope: how will the court construe the term "about" in the context of the claimed 30 mg immediate-release and 10 mg delayed-release dosages, and will the precise formulation of Lupin’s product fall within that scope?